Psyllium and bran in IBS: the type of fiber mattered
A primary-care trial found different response and dropout patterns for two fiber supplements.

Illustrative food image, not a photograph of the study intervention.
Three groups, one defined response
This primary-care trial randomized 275 adults aged 18–65 years with irritable bowel syndrome to psyllium, bran, or a rice-flour placebo for 12 weeks. The trial amounts were 10 g for each intervention, with 85 participants assigned to psyllium, 97 to bran, and 93 to placebo. These quantities describe the research protocol, not a personal dosing recommendation. The primary endpoint was adequate symptom relief during at least two weeks of the previous month. Assessments after one, two, and three months allowed the researchers to examine timing rather than treating any improvement at any visit as the same result.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ et al.. BMJ (Clinical research ed.), 2009. PMID 19713235 · DOI
The early response favored psyllium
In the first month, 57% of participants assigned to psyllium met the response definition, compared with 35% assigned to placebo. The relative risk was 1.60, with a 95% confidence interval of 1.13–2.26. During the second month, the corresponding response rates were 59% and 41%, with a relative risk of 1.44 and confidence interval of 1.02–2.06. Those results support a benefit for this particular soluble-fiber intervention over the specified placebo at these time points. They do not establish that every type of dietary fiber, or every fiber-containing food, would produce the same response in IBS.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ et al.. BMJ (Clinical research ed.), 2009. PMID 19713235 · DOI
Bran tells a less secure story
Bran exceeded placebo for the response endpoint only during the third month: 57% versus 32%, with a relative risk of 1.70 and confidence interval of 1.12–2.57. However, that comparison was no longer statistically significant in the worst-case analysis, where the relative risk was 1.45 and the interval extended from 0.97 to 2.16. Early dropout was most common in the bran group, mainly because IBS symptoms worsened. Reporting the favorable third-month percentage without these qualifications would hide important uncertainty. The abstract presents bran as a less consistent result than psyllium, not as an interchangeable substitute with identical tolerability.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ et al.. BMJ (Clinical research ed.), 2009. PMID 19713235 · DOI
Severity improved, but quality of life did not separate
After three months, symptom severity had fallen by 90 points in the psyllium group, compared with 49 points in the placebo group; that comparison had a P value of .03. The reduction with bran was 58 points, with P=.61 versus placebo. No differences were found for quality of life. Completion also limits the picture: 64% of the psyllium group, 56% of the bran group, and 60% of the placebo group completed treatment. A fair reading retains both the psyllium symptom benefit and the substantial noncompletion, without translating symptom-score changes into a demonstrated improvement across every aspect of daily life.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ et al.. BMJ (Clinical research ed.), 2009. PMID 19713235 · DOI